Dyne Therapeutics
227 hedge funds and large institutions have $3.4B invested in Dyne Therapeutics in 2026 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 100 increasing their positions, 60 reducing their positions, and 45 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 60
2% less capital invested
Capital invested by funds: $3.48B → $3.4B (-$78.1M)
7% less first-time investments, than exits
New positions opened: 42 | Existing positions closed: 45
2% less funds holding
Funds holding: 232 → 227 (-5)
10.74% less ownership
Funds ownership: 124.57% → 113.83% (-11%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
83% less call options, than puts
Call options by funds: $769K | Put options by funds: $4.47M
Top Buyers
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$71.9M |
| 2 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$22M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$20.7M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$18.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$16.7M |
DYN Hedge Fund Activity: Q1 2026 in Review
227 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2026, worth a combined $3.4B — down 2.2% from $3.48B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of DYN and 42 opened new positions — a net loss of 3 holders — while 60 trimmed existing stakes and 100 added.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $228M. The largest seller was Adage Capital Partners, cutting an estimated $71.9M.
- 227 institutional investors held Dyne Therapeutics (DYN) as of Q1 2026, down from 232 in Q4 2025.
- Funds reported $3.4B of Dyne Therapeutics stock for Q1 2026, down 2.2% quarter-over-quarter.
- 42 funds opened new Dyne Therapeutics positions in Q1 2026 and 45 closed out, a net change of -3 holders.
- The largest Dyne Therapeutics buyer in Q1 2026 was T. Rowe Price Investment Management, an estimated $228M added.
- The largest Dyne Therapeutics seller in Q1 2026 was Adage Capital Partners, an estimated $71.9M sold.
Based on aggregated 13F filings for Q1 2026.